| Birju D Shah, MD | |
|
10800 Magnolia Ave, Riverside, CA 92505-3043 | |
| (909) 353-2000 | |
| Not Available |
| Full Name | Birju D Shah |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 19 Years |
| Location | 10800 Magnolia Ave, Riverside, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053692384 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A117479 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital, Riverside | Riverside, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
People with untreated hearing loss lose as much as $30,000 in income annually, depending on their degree of hearing loss, according to the latest national study by the Better Hearing Institute. And the cost to society is estimated to be as high as $26 billion in unrealized federal taxes.
A selection of health policy stories from Connecticut, California, Vermont, Minnesota, Virginia and Georgia.
Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.
Investigators from the Institute for Research in Immunology and Cancer at the Université de Montréal have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood.
› Verified 5 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
People with untreated hearing loss lose as much as $30,000 in income annually, depending on their degree of hearing loss, according to the latest national study by the Better Hearing Institute. And the cost to society is estimated to be as high as $26 billion in unrealized federal taxes.
A selection of health policy stories from Connecticut, California, Vermont, Minnesota, Virginia and Georgia.
Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.
Investigators from the Institute for Research in Immunology and Cancer at the Université de Montréal have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Birju D Shah, MD 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (909) 353-2000 | Birju D Shah, MD 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (909) 353-2000 |
News Archive
People with untreated hearing loss lose as much as $30,000 in income annually, depending on their degree of hearing loss, according to the latest national study by the Better Hearing Institute. And the cost to society is estimated to be as high as $26 billion in unrealized federal taxes.
A selection of health policy stories from Connecticut, California, Vermont, Minnesota, Virginia and Georgia.
Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.
Investigators from the Institute for Research in Immunology and Cancer at the Université de Montréal have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood.
› Verified 5 days ago
Sang Kun Yim, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7117 Brockton Ave, Riverside, CA 92506 Phone: 951-683-6370 | |
Sarah Chae, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4646 Brockton Ave Ste 201, Riverside, CA 92506 Phone: 951-585-1800 Fax: 951-585-1801 | |
Alina S Popa, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4445 Magnolia Ave, Riverside, CA 92501 Phone: 951-788-3636 | |
Richard M. Bradburne, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Shelly C. Thio, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Fawaz Gailani, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Andrew Duke, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 4445 Magnolia Ave, Riverside, CA 92501 Phone: 951-788-3000 |